fbpx
Wikipedia

Prevention of HIV/AIDS

May 02, 2024

HIV prevention refers to practices that aim to prevent the spread of the human immunodeficiency virus (HIV). HIV prevention practices may be undertaken by individuals to protect their own health and the health of those in their community, or may be instituted by governments and community-based organizations as public health policies.

Prevention strategies edit

Interventions for the prevention of HIV include the use of:

 
AIDS Prevention - Condom dispensers in toilets

The consistent, correct use of condoms is one proven method for preventing the spread of HIV during sexual intercourse.[6] In high income countries, Prevention of Mother to Child Transmission Programs (PMTC) including HIV testing of pregnant women, antiretroviral treatment,[7] counselling about infant feeding, and safe obstetric practices (avoiding invasive procedures) have reduced mother-to-child transmission to less than 1%.

Treatment as prevention (TasP) is also effective; in sero-different couples (where one partner is HIV-positive and the other is HIV negative), HIV is significantly less likely to be transmitted to the uninfected partner if the HIV positive partner is on treatment.[8] It is now known that an if HIV-positive person has an undetectable viral load, there is no risk of HIV transmission to a sexual partner[9][10][11]

Increased risk of contracting HIV correlates with the presence of co-infections, particularly other sexually transmissible infections. Medical professionals recommend treatment or prevention of other infections such as herpes, hepatitis A, hepatitis B, hepatitis C, human papillomavirus, syphilis, gonorrhea, and tuberculosis as an indirect way to prevent the spread of HIV infection. Doctors treat these conditions with pharmaceutical interventions and/or vaccination.[12] Nevertheless, it is not known if treating other sexually transmitted infections on a population scale is effective in preventing HIV.[13]

Harm reduction and social strategies edit

Harm reduction is defined as "policies, programmes and practices that aim to minimise negative health, social and legal impacts associated with drug use, drug policies and drug laws".[14] The World Health Organization (WHO) recognizes that harm reduction is central to the prevention of HIV amongst people who inject drugs (PWID) and their sexual and drug using partners.[15] Social strategies do not require any drug or object to be effective, but rather require persons to change their behaviors to gain protection from HIV. Some social strategies include:[citation needed]

Each of these strategies has widely differing levels of efficacy, social acceptance, and acceptance in the medical and scientific communities.[citation needed]

Populations who access HIV testing are less likely to engage in behaviors with high risk of contracting HIV,[16] so HIV testing is almost always a part of any strategy to encourage people to change their behaviors to become less likely to contract HIV. Over 60 countries impose some form of travel restriction, either for short or long-term stays, for people infected with HIV.[17]

Advertising and campaigns edit

Persuasive messages delivered through health advertising and social marketing campaigns which are designed to educate people about the risks of HIV/AIDS and simple prevention strategies are also an important way of preventing HIV. These persuasive messages have successfully increased people's knowledge about HIV. More importantly, information sent out through advertising and social marketing also proves to be effective in promoting more favorable attitudes and intentions toward future condom use, though they did not bring significant change in actual behaviors except those were targeting at specific behavioral skills.[18][19]

A 2020 systematic review of 16 studies found that financial education improved self-efficacy and lowered vulnerability to HIV in young people in low and middle income countries. Many of the studies in the review combined financial education with sexual health education and/or counselling.[20]

Research in health communication also found that importance of advocating critical skills and informing available resources are higher for people with lower social power, but not necessarily true for people with more power. African American audiences need to be educated about strategies they could take to efficiently manage themselves in health behaviors such as mood control, management of drugs, and proactive planning for sexual behaviors. However, these things are not as important for European Americans.[19]

Sexual contact edit

Condoms and gels edit

 
Condom in the shape of an AIDS ribbon
 
Various personal lubricants

Consistent condom use reduces the risk of heterosexual HIV transmission by about 80% over the long-term.[21] Where one partner of a couple has HIV infection, consistent condom use results in rates of HIV infection for the uninfected person below 1% per year.[22] Some data support the equivalence of internal condoms to latex condoms, but the evidence is not definitive.[23] As of January 2019, condoms are available inside 30% of prisons globally.[24] Use of the spermicide nonoxynol-9 may increase the risk of transmission because it causes vaginal and rectal irritation.[25] A vaginal gel containing tenofovir, a reverse transcriptase inhibitor, when used immediately before sex, was shown to reduce infection rates by roughly 40% among African women.[26]

Voluntary male circumcision edit

 
South Africa 1 millionth voluntary medical male circumcision

Studies conducted in sub-Saharan Africa have found that circumcision reduces the risk of HIV infection in heterosexual men between 38 and 66% over two years.[27] Based on these studies, the World Health Organization and UNAIDS both recommended male circumcision as a method of preventing female-to-male HIV transmission in 2007.[28] Whether it protects against male-to-female transmission is disputed[29][30] and whether it is of benefit in developed countries and among men who have sex with men is undetermined.[31][32][33] For men who have sex with men there is some evidence that the penetrative partner has a lower chance of contracting HIV.[34] Some experts fear that a lower perception of vulnerability among circumcised men may result in more sexual risk-taking behavior, thus negating its preventive effects.[35] Women who have undergone female genital cutting have an increased risk of HIV.[36]

The African studies on which this information is based have been criticized for methodological flaws.[37] Svoboda and Howe compare them to the "lowest common denominator", citing "selection bias, randomization bias, experimenter bias, inadequate blinding, participant expectation bias, lack of placebo control, inadequate equipoise, excessive attrition of subjects, failure to investigate non-sexual HIV transmission, lead time bias, and time-out discrepancy." In addition, the 60% figure for risk reduction is dismissed as relative and misleading, with an absolute figure of only 1.3%, which is considered effectively meaningless given the "background noise produced by numerous sources of bias". They also point out that the United States has both the highest rates of circumcision and HIV/STD infections in the industrialized world, casting serious doubt that the former prevents the latter. There are also major epidemiological differences between regions: in Africa, HIV is commonly spread via inadequate infection prevention practices in health clinics, while in the US, the primary routes of infection are sharing equipment amongst people who use drugs and condomless anal intercourse among MSM. Additional criticisms are offered by George Hill:[38] "Our results clearly show that these African CRFs were methodologically flawed from start to finish... From the start, there was almost nothing correct with these studies. It was quite clear that these studies were unethical. They would never have been approved by a single ethics committee in the United States."

Education and health promotion edit

Programs encouraging sexual abstinence do not appear to affect subsequent HIV risk in high-income countries.[39] Evidence for a benefit from peer education is equally poor.[40] Comprehensive sexual education provided at school may decrease high risk behavior.[41] A substantial minority of young people continue to engage in high-risk practices despite HIV/AIDS knowledge, underestimating their own risk of becoming infected with HIV.[42]

Before exposure edit

Early treatment of HIV-infected people with antiretrovirals protected 96% of partners from infection.[43][8] Pre-exposure prophylaxis with a daily dose of tenofovir with or without emtricitabine is effective in a number of groups, including men who have sex with men, couples where one is HIV positive, and young heterosexuals in Africa.[26]

Universal precautions within the health-care environment are believed to be effective in decreasing the risk of HIV.[44] Intravenous drug use is an important risk factor and harm reduction strategies such as needle-exchange programmes and opioid substitution therapy appear effective in decreasing this risk.[45]

Needle exchange programs (also known as syringe exchange programs) are effective in preventing HIV among IDUs and in the broader community.[46] Pharmacy sales of syringes and physician prescription of syringes have been also found to reduce HIV risk.[47] Supervised injection facilities are also understood to address HIV risk in the most-at-risk populations.[48] Multiple legal and attitudinal barriers limit the scale and coverage of these "harm reduction" programs in the United States and elsewhere around the world.[48]

The American Centers for Disease Control and Prevention (CDC) conducted a study in partnership with the Thailand Ministry of Public Health to ascertain the effectiveness of providing people who inject drugs illicitly with daily doses of the antiretroviral drug tenofovir as a prevention measure. The results of the study revealed a 48.9% reduced incidence of the virus among the group of subjects who received the drug, in comparison to the control group who received a placebo. The principal investigator of the study stated in the Lancet medical journal: "We now know that pre-exposure prophylaxis can be a potentially vital option for HIV prevention in people at very high risk for infection, whether through sexual transmission or injecting drug use."[49]

After exposure edit

A course of antiretrovirals administered within 48 to 72 hours after exposure to HIV-positive blood or genital secretions is referred to as post-exposure prophylaxis.[50] The use of the single agent zidovudine reduces the risk of subsequent HIV infection fivefold following a needle stick injury.[50] Treatment is recommended after sexual assault when the perpetrators are known to be HIV positive, but is controversial when their HIV status is unknown.[51] Current treatment regimens typically use lopinavir/ritonavir and lamivudine/zidovudine or emtricitabine/tenofovir and may decrease the risk further.[50] The duration of treatment is usually four weeks[52] and is associated with significant rates of adverse effects (for zidovudine about 70% including: nausea 24%, fatigue 22%, emotional distress 13%, and headaches 9%).[53]

Follow-up care edit

Strategies to reduce recurrence rates of HIV have been successful in preventing reinfection. Treatment facilities encourage those previously treated for HIV return to ensure that the infection is being successfully managed. New strategies to encouraging retesting have been the use of text messaging and email. These methods of recall are now used along with phone calls and letters.[54]

Mother-to-child edit

Programs to prevent the transmission of HIV from mothers to children can reduce rates of transmission by 92–99%.[45][55] This primarily involves the use of a combination of antivirals during pregnancy and after birth in the infant but also potentially include bottle feeding rather than breastfeeding.[55][56] If replacement feeding is acceptable, feasible, affordable, sustainable and safe mothers should avoid breast-feeding their infants; however, exclusive breast-feeding is recommended during the first months of life if this is not the case.[57] If exclusive breast feeding is carried out the provision of extended antiretroviral prophylaxis to the infant decreases the risk of transmission.[58]

Vaccination edit

 
Various approaches for HIV vaccine development

As of 2020, no effective vaccine for HIV or AIDS is known.[59] A single trial of the vaccine RV 144 found a partial efficacy rate around 30% and has stimulated optimism in the research community regarding developing a truly effective vaccine.[60] Further trials of the vaccine are ongoing.[61][62]

Gene therapy edit

Certain mutations on the CCR5 gene have been known to make certain people unable to catch AIDS. Modifying the CCR5 gene using gene therapy can thus make people unable to catch it either.[63][64]

Legal system edit

Laws criminalizing HIV transmission have not been found an effective way to reduce HIV risk behavior, and may actually do more harm than good. In the past, many U.S. states criminalized the possession of needles without a prescription, even going so far as to arrest people as they leave private needle-exchange facilities.[65] In jurisdictions where syringe prescription status presented a legal barrier to access, physician prescription programs had shown promise in addressing risky injection behaviors.[66] Epidemiological research demonstrating that syringe access programs are both effective and cost-effective helped change state and local laws relating to needle-exchange program (NEP) operations and the status of syringe possession more broadly.[67] As of 2006, 48 states in the United States authorized needle exchange in some form or allowed the purchase of sterile syringes without a prescription at pharmacies.[68]

Removal of legal barriers to operation of NEPs and other syringe access initiatives has been identified as an important part of a comprehensive approach to reducing HIV transmission among injection drug users (IDUs).[67] Legal barriers include both "law on the books" and "law on the streets", i.e., the actual practices of law enforcement officers,[69][70] which may or may not reflect the formal law. Changes in syringe and drug-control policy can be ineffective in reducing such barriers if police continue to treat syringe possession as a crime or participation in NEP as evidence of criminal activity. [71] Although most NEPs in the US are now operating legally, many report some form of police interference.[71]

Research elsewhere has shown similar misalignment between "law on the books" and "law on the streets". For example, in Kyrgyzstan, although sex work, syringe sales, and possession of syringes are not criminalized and possession of small drug amounts has been decriminalized, gaps remain between these policies and law enforcement knowledge and practice.[72][73][74] To optimize public health efforts targeting vulnerable groups, law enforcement personnel and public health policies should be closely aligned. Such alignment can be improved through policy, training, and coordination efforts.[74]

Quality in prevention edit

The EU-wide Joint Action on Improving Quality in HIV Prevention is seeking to increase the effectiveness of HIV prevention in Europe by using practical quality assurance (QA) and quality improvement (QI) tools.[75]

History edit

1980s edit

The Centers for Disease Control was the first organization to recognize the pandemic which came to be called AIDS.[76] Their announcement came on June 5, 1981, when one of their journals published an article reporting five cases of pneumonia, caused by Pneumocystis jirovecii, all in gay men living in Los Angeles.[77][78]

In May 1983, scientists isolated a retrovirus which was later called HIV from an AIDS patient in France.[79] At this point, the disease called AIDS was proposed to be caused by HIV, and people began to consider prevention of HIV infection as a strategy for preventing AIDS.[citation needed]

In the 1980s, public policy makers and most of the public could not understand that the overlap of sexual and needle-sharing networks with the general community had somehow lead to many thousands of people worldwide becoming infected with HIV.[76] In many countries, leaders and most of the general public denied both that AIDS and the risk behaviors which spread HIV existed outside of concentrated populations.[76]

In 1987, the United States FDA approved AZT as the first pharmaceutical treatment for AIDS.[80] Around the same time, ACT UP was formed, with one of the group's first goals being to find a way to get access to pharmaceutical drugs to treat HIV.[81] When AZT was made publicly available, it was extremely expensive and unaffordable to all but the most wealthy AIDS patients.[82] The availability of medicine but the lack of access to it sparked large protests around FDA offices.[83][84]

From 2003 edit

In 2003, Swaziland and Botswana reported nearly four out of 10 people were HIV positive.[85] Festus Mogae, president of Botswana, admitted huge infrastructure problems to the international community and requested foreign intervention in the form of consulting in health care setup and antiretroviral drug distribution programs.[86] In Swaziland, the government chose not to immediately address the problem in the way that international health agencies advised, so many people died.[87] In world media, the governments of African countries began to similarly be described as participating in the effort to prevent HIV actively or less actively.

There came to be international discussion about why HIV rates in Africa were so high, because if the cause were known, then prevention strategies could be developed. Previously, some researchers had suggested that HIV in Africa was widespread because of unsafe medical practices which somehow transferred blood to patients through procedures such as vaccination, injection, or reuse of equipment. In March 2003, the WHO released a statement that almost all infections were, in fact, the result of unsafe practices in heterosexual intercourse.[88]

In response to the rising HIV rates, Cardinal Alfonso López Trujillo, speaking on behalf of the Vatican, said that not only was the use of condoms immoral, but also that condoms were ineffective in preventing HIV.[89] The cardinal was highly criticized by the world health community, who were trying to promote condom use as a way to prevent the spread of HIV.[90][91] The WHO later conducted a study showing that condoms are 90% effective at preventing HIV.[89]

In 2001, the United States began a war in Afghanistan related to fighting the Taliban. The Taliban, however, had opposed local opium growers and the heroin trade; when the government of Afghanistan fell during the war, opium production was unchecked. By 2003, the world market had an increase in the available heroin supply; in former Soviet states especially, an increase in HIV infection was due to injection drug use. Efforts were renewed to prevent HIV related to sharing needles.[92][93][94][95]

From 2011 edit

In July 2011, it was announced by the WHO and UNAIDS that a once-daily antiretroviral tablet could significantly reduce the risk of HIV transmission in heterosexual couples.[96] These findings were based on the results of two trials conducted in Kenya and Uganda, and Botswana.

The Partners PrEP (pre-exposure prophylaxis) trial was funded by the Bill & Melinda Gates Foundation[97] and conducted by the International Clinical Research Center at the University of Washington. The trial followed 4758 heterosexual couples in Kenya and Uganda, in which one individual was HIV positive and the other was HIV negative.[96] The uninfected (HIV negative) partner was given either a once-daily tenofovir tablet, a once-daily combination tablet of tenofovir and emtricitabine, or a placebo tablet containing no antiretroviral drug. These couples also received counselling and had access to free male and female condoms. In couples taking tenofovir and tenofovir/emtricitabine, there was a 62% and 73% decrease, respectively, in the number of HIV infections as compared to couples who were receiving the placebo.[96]

A similar result was observed with the TDF2 trial, conducted by the United States Centers for Disease Control in partnership with the Botswana Ministry of Health.[98] The trial followed 1200 HIV negative men and women in Francistown, Botswana, a city known to have one of the world's highest HIV infection rates.[98] Participants received either a once-daily tenofovir/emtricitabine combination tablet or a placebo. In those taking the antiretroviral treatment, there was found to be a 63% decrease in the risk of acquiring HIV, as compared to those receiving the placebo.[96]

The HIV-1 virus has proved to be tenacious, inserting its genome permanently into patients' DNA, forcing patients to take a lifelong drug regimen to control the virus and prevent a fresh attack. Now, a team of Temple University School of Medicine researchers have designed a way to "snip out" the integrated HIV-1 genes for good. This is one important step on the path toward a permanent cure for AIDS. This is the first successful attempt to eliminate latent HIV-1 virus from human cells.

In a study published by the Proceedings of the National Academy of Sciences (PNAS), Khalili and colleagues detail how they created molecular tools to delete the HIV-1 proviral DNA.[full citation needed] When deployed, a combination of DNA-snipping enzyme called a nuclease and targeting strand of RNA called a guide RNA (gRNA) hunt down the viral genome and excise the HIV-1 DNA. From there, the cell's own gene repair machinery takes over, soldering the loose ends of the genome back together – resulting in virus-free cells.[citation needed]

Since HIV-1 is never cleared by the immune system, removal of the virus is required in order to cure the disease. The same technique could theoretically be used against a variety of viruses. The research shows that these molecular tools also hold promise as a therapeutic vaccine; cells armed with the nuclease-RNA combination proved impervious to HIV infection.

See also edit

References edit

  1. ^ "How to Use a Female Condom | CDC". www.cdc.gov. 2019-02-22. Retrieved 2019-10-31.
  2. ^ "How to Use a Male Condom | CDC". www.cdc.gov. 2019-02-22. Retrieved 2019-10-31.
  3. ^ "How to Use a Dental Dam | CDC". www.cdc.gov. 2019-02-22. Retrieved 2019-10-31.
  4. ^ Nandra I (28 March 2008). . who.int. Archived from the original on April 11, 2007. Retrieved 3 July 2011.
  5. ^ Siegfried N, Muller M, Deeks JJ, Volmink J (April 2009). Cochrane HIV/AIDS Group (ed.). "Male circumcision for prevention of heterosexual acquisition of HIV in men". The Cochrane Database of Systematic Reviews (2): CD003362. doi:10.1002/14651858.CD003362.pub2. PMID 19370585.
  6. ^ Weller S, Davis K, et al. (Cochrane HIV/AIDS Group) (2002-01-21). "Condom effectiveness in reducing heterosexual HIV transmission". The Cochrane Database of Systematic Reviews. 2012 (1): CD003255. doi:10.1002/14651858.CD003255. PMC 8407100. PMID 11869658.
  7. ^ White AB, Mirjahangir JF, Horvath H, Anglemyer A, Read JS (October 2014). Cochrane HIV/AIDS Group (ed.). "Antiretroviral interventions for preventing breast milk transmission of HIV". The Cochrane Database of Systematic Reviews. 2014 (10): CD011323. doi:10.1002/14651858.CD011323. PMC 10576873. PMID 25280769.
  8. ^ a b Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, Siegfried N, et al. (Cochrane HIV/AIDS Group) (April 2013). "Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples". The Cochrane Database of Systematic Reviews. 4 (4): CD009153. doi:10.1002/14651858.CD009153.pub3. PMC 4026368. PMID 23633367.
  9. ^ Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C (September 2005). "Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV". Journal of Acquired Immune Deficiency Syndromes. 40 (1): 96–101. doi:10.1097/01.qai.0000157389.78374.45. PMID 16123689. S2CID 42271802.
  10. ^ Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. (July 2016). "Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy". JAMA. 316 (2): 171–81. doi:10.1001/jama.2016.5148. PMID 27404185.
  11. ^ Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. (June 2019). "Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study". Lancet. 393 (10189): 2428–2438. doi:10.1016/S0140-6736(19)30418-0. PMC 6584382. PMID 31056293.
  12. ^ "Home - Australian STI Management Guidelines". www.sti.guidelines.org.au. Retrieved 2020-07-25.
  13. ^ Ng BE, Butler LM, Horvath T, Rutherford GW (March 2011). "Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection". The Cochrane Database of Systematic Reviews (3): CD001220. doi:10.1002/14651858.CD001220.pub3. PMID 21412869.
  14. ^ "What is harm reduction?". Harm Reduction International. Retrieved 2020-02-25.
  15. ^ "Harm reduction". www.euro.who.int. 2020-02-25. Retrieved 2020-02-25.
  16. ^ Weinhardt LS, Carey MP, Johnson BT, Bickham NL (September 1999). "Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997". American Journal of Public Health. 89 (9): 1397–405. doi:10.2105/ajph.89.9.1397. PMC 1508752. PMID 10474559.
  17. ^ "HIVTravel - Regulations on Entry, Stay, and Residence for PLHIV". Retrieved 2012-02-26.
  18. ^ Albarracín D, McNatt PS, Klein CT, Ho RM, Mitchell AL, Kumkale GT (March 2003). "Persuasive communications to change actions: an analysis of behavioral and cognitive impact in HIV prevention". Health Psychology. 22 (2): 166–77. doi:10.1037/0278-6133.22.2.166. PMC 4803280. PMID 12683737.
  19. ^ a b Albarracín D, Gillette JC, Earl AN, Glasman LR, Durantini MR, Ho MH (November 2005). "A test of major assumptions about behavior change: a comprehensive look at the effects of passive and active HIV-prevention interventions since the beginning of the epidemic". Psychological Bulletin. 131 (6): 856–97. doi:10.1037/0033-2909.131.6.856. PMC 2713787. PMID 16351327.
  20. ^ Lee N, Beeler Stücklin S, Lopez Rodriguez P, El Alaoui Faris M, Mukaka I (2020). "Financial education for HIV-vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence". Campbell Systematic Reviews. 16 (1): e1071. doi:10.1002/cl2.1071. ISSN 1891-1803. PMC 8356319.
  21. ^ Crosby R, Bounse S (March 2012). "Condom effectiveness: where are we now?". Sexual Health. 9 (1): 10–7. doi:10.1071/SH11036. PMID 22348628.
  22. ^ . WHO. August 2003. Archived from the original on October 18, 2012. Retrieved January 17, 2006.
  23. ^ Gallo MF, Kilbourne-Brook M, Coffey PS (March 2012). "A review of the effectiveness and acceptability of the female condom for dual protection". Sexual Health. 9 (1): 18–26. doi:10.1071/SH11037. PMID 22348629.
  24. ^ Moazen, B, Owusu, PN, Wiessner, P and Stöver, H. (2019), Coverage and Barriers Towards Condom Provision in Prisons: A Review of the EvidenceAvailability, Coverage and Barriers Towards Condom Provision in Prisons: A Review of the EvidenceInstitut für Suchtforschung (ISFF), Frankfurt, University of Applied Sciences.
  25. ^ Baptista M, Ramalho-Santos J (November 2009). "Spermicides, microbicides and antiviral agents: recent advances in the development of novel multi-functional compounds". Mini Reviews in Medicinal Chemistry. 9 (13): 1556–67. doi:10.2174/138955709790361548. PMID 20205637.
  26. ^ a b Celum C, Baeten JM (February 2012). "Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence". Current Opinion in Infectious Diseases. 25 (1): 51–7. doi:10.1097/QCO.0b013e32834ef5ef. PMC 3266126. PMID 22156901.
  27. ^ Siegfried N, Muller M, Deeks JJ, Volmink J (April 2009). "Male circumcision for prevention of heterosexual acquisition of HIV in men". The Cochrane Database of Systematic Reviews (2): CD003362. doi:10.1002/14651858.CD003362.pub2. PMID 19370585.
  28. ^ . World Health Organization. Mar 28, 2007. Archived from the original on April 11, 2007.
  29. ^ Larke N (May 2010). "Male circumcision, HIV and sexually transmitted infections: a review". British Journal of Nursing. 19 (10): 629–34. doi:10.12968/bjon.2010.19.10.48201. PMC 3836228. PMID 20622758.
  30. ^ Eaton L, Kalichman SC (November 2009). "Behavioral aspects of male circumcision for the prevention of HIV infection". Current HIV/AIDS Reports. 6 (4): 187–93. doi:10.1007/s11904-009-0025-9. PMC 3557929. PMID 19849961.
  31. ^ Kim HH, Li PS, Goldstein M (November 2010). "Male circumcision: Africa and beyond?". Current Opinion in Urology. 20 (6): 515–9. doi:10.1097/MOU.0b013e32833f1b21. PMID 20844437. S2CID 2158164.
  32. ^ Templeton DJ, Millett GA, Grulich AE (February 2010). "Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men". Current Opinion in Infectious Diseases. 23 (1): 45–52. doi:10.1097/QCO.0b013e328334e54d. PMID 19935420. S2CID 43878584.
  33. ^ Wiysonge CS, Kongnyuy EJ, Shey M, Muula AS, Navti OB, Akl EA, Lo YR (June 2011). Wiysonge CS (ed.). "Male circumcision for prevention of homosexual acquisition of HIV in men". The Cochrane Database of Systematic Reviews (6): CD007496. doi:10.1002/14651858.CD007496.pub2. PMID 21678366.
  34. ^ . Archived from the original on 2014-06-25. Retrieved 2014-06-13.
  35. ^ Eaton LA, Kalichman S (December 2007). "Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies". Current HIV/AIDS Reports. 4 (4): 165–72. doi:10.1007/s11904-007-0024-7. PMC 2937204. PMID 18366947.
  36. ^ Utz-Billing I, Kentenich H (December 2008). "Female genital mutilation: an injury, physical and mental harm". Journal of Psychosomatic Obstetrics and Gynaecology. 29 (4): 225–9. doi:10.1080/01674820802547087. PMID 19065392. S2CID 36904088.
  37. ^ Svoboda, Steven; Van Howe, Robert (July 2013). "Out of Step: Fatal Flaws in the Latest AAP Policy Report on Neonatal Circumcision". Journal of Medical Ethics. 39 (7). BMJ: 434–441. doi:10.1136/medethics-2013-101346. JSTOR 43282781. PMID 23508208. S2CID 39693618.
  38. ^ Boyle, G. J.; Hill, G. (2011). "Sub-Saharan African randomised clinical trials into male circumcision and HIV transmission: Methodological, ethical and legal concerns". Journal of Law and Medicine. 19 (2): 316–34. PMID 22320006.
  39. ^ Underhill K, Operario D, Montgomery P (October 2007). "Abstinence-only programs for HIV infection prevention in high-income countries". The Cochrane Database of Systematic Reviews (4): CD005421. doi:10.1002/14651858.CD005421.pub2. PMID 17943855.
  40. ^ Tolli MV (October 2012). "Effectiveness of peer education interventions for HIV prevention, adolescent pregnancy prevention and sexual health promotion for young people: a systematic review of European studies". Health Education Research. 27 (5): 904–13. doi:10.1093/her/cys055. PMID 22641791.
  41. ^ Ljubojević S, Lipozenčić J (2010). "Sexually transmitted infections and adolescence". Acta Dermatovenerologica Croatica. 18 (4): 305–10. PMID 21251451.
  42. ^ Patel VL, Yoskowitz NA, Kaufman DR, Shortliffe EH (September 2008). "Discerning patterns of human immunodeficiency virus risk in healthy young adults". The American Journal of Medicine. 121 (9): 758–64. doi:10.1016/j.amjmed.2008.04.022. PMC 2597652. PMID 18724961.
  43. ^ National Institute of Allergy and Infectious Diseases (NIAID), "Treating HIV-infected People with Antiretrovirals Protects Partners from Infection", NIH News, 2011 May
  44. ^ Centers for Disease Control (CDC) (August 1987). "Recommendations for prevention of HIV transmission in health-care settings". MMWR Supplements. 36 (2): 1S–18S. PMID 3112554.
  45. ^ a b Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN (March 2011). "Combination HIV prevention: significance, challenges, and opportunities". Current HIV/AIDS Reports. 8 (1): 62–72. doi:10.1007/s11904-010-0063-3. PMC 3036787. PMID 20941553.
  46. ^ World Health Organization. "Effectiveness of Sterile Needle and Syringe Programming in Reducing HIV/AIDS Among Injecting Drug Users" (PDF). Evidence for Action Technical Papers. Retrieved 7 January 2012.
  47. ^ Macalino GE, Sachdev DD, Rich JD, Becker C, Tan LJ, Beletsky L, Burris S (June 2009). "A national physician survey on prescribing syringes as an HIV prevention measure". Substance Abuse Treatment, Prevention, and Policy. 4: 13. doi:10.1186/1747-597X-4-13. PMC 2700789. PMID 19505336.
  48. ^ a b Beletsky L, Davis CS, Anderson E, Burris S (February 2008). "The law (and politics) of safe injection facilities in the United States". American Journal of Public Health. 98 (2): 231–7. doi:10.2105/ajph.2006.103747. PMC 2376869. PMID 18172151. SSRN 1088019.
  49. ^ Bourke E (14 June 2013). "Preventive drug could reduce HIV transmission among injecting drug users". The Conversation Australia. The Conversation Media Group. Retrieved 17 June 2013.
  50. ^ a b c "HIV exposure through contact with body fluids". Prescrire International. 21 (126): 100–1, 103–5. April 2012. PMID 22515138.
  51. ^ Linden JA (September 2011). "Clinical practice. Care of the adult patient after sexual assault". The New England Journal of Medicine. 365 (9): 834–41. doi:10.1056/NEJMcp1102869. PMID 21879901.
  52. ^ Young TN, Arens FJ, Kennedy GE, Laurie JW, Rutherford GW (January 2007). "Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure". The Cochrane Database of Systematic Reviews. 2012 (1): CD002835. doi:10.1002/14651858.CD002835.pub3. PMC 8989146. PMID 17253483.
  53. ^ Kripke C (August 2007). "Antiretroviral prophylaxis for occupational exposure to HIV". American Family Physician. 76 (3): 375–6. PMID 17708137.
  54. ^ Desai M, Woodhall SC, Nardone A, Burns F, Mercey D, Gilson R (August 2015). "Active recall to increase HIV and STI testing: a systematic review". Sexually Transmitted Infections. 91 (5): 314–23. doi:10.1136/sextrans-2014-051930. PMID 25759476.
  55. ^ a b Coutsoudis A, Kwaan L, Thomson M (October 2010). "Prevention of vertical transmission of HIV-1 in resource-limited settings". Expert Review of Anti-Infective Therapy. 8 (10): 1163–75. doi:10.1586/eri.10.94. PMID 20954881. S2CID 46624541.
  56. ^ Siegfried N, van der Merwe L, Brocklehurst P, Sint TT (July 2011). "Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection". The Cochrane Database of Systematic Reviews (7): CD003510. doi:10.1002/14651858.CD003510.pub3. PMID 21735394.
  57. ^ "WHO HIV and Infant Feeding Technical Consultation Held on behalf of the Inter-agency Task Team (IATT) on Prevention of HIV – Infections in Pregnant Women, Mothers and their Infants – Consensus statement" (PDF). October 25–27, 2006. (PDF) from the original on April 9, 2008. Retrieved March 12, 2008.
  58. ^ Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS (January 2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV". The Cochrane Database of Systematic Reviews. 2009 (1): CD006734. doi:10.1002/14651858.CD006734.pub2. PMC 7389566. PMID 19160297.
  59. ^ UNAIDS (May 18, 2012). "The quest for an HIV vaccine".
  60. ^ Reynell L, Trkola A (2012-03-02). "HIV vaccines: an attainable goal?". Swiss Medical Weekly. 142: w13535. doi:10.4414/smw.2012.13535. PMID 22389197.
  61. ^ U.S. Army Office of the Surgeon General (March 21, 2011). "HIV Vaccine Trial in Thai Adults". ClinicalTrials.gov. Retrieved June 28, 2011.
  62. ^ U.S. Army Office of the Surgeon General (June 2, 2010). "Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial". ClinicalTrials.gov.
  63. ^ Cornu TI, Mussolino C, Bloom K, Cathomen T (2015). "Editing CCR5: a novel approach to HIV gene therapy". Gene Therapy for HIV and Chronic Infections. Advances in Experimental Medicine and Biology. Vol. 848. pp. 117–30. doi:10.1007/978-1-4939-2432-5_6. ISBN 978-1-4939-2431-8. PMID 25757618.
  64. ^ "Gene Therapy for Controlling HIV Shows Early Promise". WebMD.
  65. ^ Case P, Meehan T, Jones TS (1998). "Arrests and incarceration of injection drug users for syringe possession in Massachusetts: implications for HIV prevention". Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 18 (Suppl 1): S71-5. doi:10.1097/00042560-199802001-00013. PMID 9663627.
  66. ^ Macalino GE, Sachdev DD, Rich JD, Becker C, Tan LJ, Beletsky L, Burris S (June 2009). "A national physician survey on prescribing syringes as an HIV prevention measure". Substance Abuse Treatment, Prevention, and Policy. 4 (1): 13. doi:10.1186/1747-597X-4-13. PMC 2700789. PMID 19505336.
  67. ^ a b Burris S, Finucane D, Gallagher H, Grace J (August 1996). "The legal strategies used in operating syringe exchange programs in the United States". American Journal of Public Health. 86 (8): 1161–6. doi:10.2105/ajph.86.8_pt_1.1161. PMC 1380633. PMID 8712281.
  68. ^ Chris Barrish (10 June 2006). . The News Journal. pp. A1, A5. Archived from the original on 2 September 2006. Retrieved 10 June 2006.
  69. ^ Burris S, Blankenship KM, Donoghoe M, Sherman S, Vernick JS, Case P, et al. (2004). "Addressing the "risk environment" for injection drug users: the mysterious case of the missing cop". The Milbank Quarterly. 82 (1): 125–56. doi:10.1111/j.0887-378x.2004.00304.x. PMC 2690204. PMID 15016246. SSRN 937013.
  70. ^ Beletsky L, Burris S, Macalino GE (2005). "Attitudes of Police Officers Towards Syringe Access, Occupational Needle-Sticks, and Drug Use: A Qualitative Study of One City Police Department in the United States". Int'l. J. Drug Pol'y. 16 (4): 267–274. doi:10.1016/j.drugpo.2005.01.009. S2CID 57946984. SSRN 872756.
  71. ^ a b Beletsky L, Grau LE, White E, Bowman S, Heimer R (February 2011). "The roles of law, client race and program visibility in shaping police interference with the operation of US syringe exchange programs". Addiction. 106 (2): 357–65. doi:10.1111/j.1360-0443.2010.03149.x. PMC 3088513. PMID 21054615.
  72. ^ CIS News (2009). "Kyrgyzstan takes an official course towards humanization of its policy towards drug users". {{cite journal}}: Cite journal requires |journal= (help)
  73. ^ Eurasian Harm Reduction Network (2011). "Implementation of the political declaration and plan of action on international cooperation towards an integrated and balanced strategy to counter the world drug problem". Eurasian Harm Reduction Network.
  74. ^ a b Beletsky L, Thomas R, Smelyanskaya M, Artamonova I, Shumskaya N, Dooronbekova A, et al. (December 2012). "Policy reform to shift the health and human rights environment for vulnerable groups: the case of Kyrgyzstan's Instruction 417". Health and Human Rights. 14 (2): 34–48. PMID 23568946.
  75. ^ "Quality Action". www.qualityaction.eu.
  76. ^ a b c Merson MH, O'Malley J, Serwadda D, Apisuk C (August 2008). "The history and challenge of HIV prevention". Lancet. 372 (9637): 475–88. doi:10.1016/S0140-6736(08)60884-3. PMID 18687461. S2CID 26554589.
  77. ^ Anonymous (1981). "Pneumocystis pneumonia—Los Angeles". Morbidity and Mortality Weekly Report (30): 250–52.
  78. ^ Sepkowitz KA (June 2001). "AIDS--the first 20 years". The New England Journal of Medicine. 344 (23): 1764–72. doi:10.1056/NEJM200106073442306. PMID 11396444.
  79. ^ Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. (May 1983). "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)". Science. 220 (4599): 868–71. Bibcode:1983Sci...220..868B. doi:10.1126/science.6189183. JSTOR 1690359. PMID 6189183. S2CID 390173.
  80. ^ Brown J (20 March 1987). . aegis.com. AIDS Education Global Information System. Archived from the original on 29 June 2011. Retrieved 2 July 2011.
  81. ^ "ACT UP 1987 Wall Street Action - List of Demands". actupny.org. March 1987. Retrieved 2 July 2011.
  82. ^ "ACT UP/ NY Chronology 1989". actupny.org. 2003. Retrieved 2 July 2011.
  83. ^ "Police Arrest AIDS Protesters Blocking Access to FDA Offices". Los Angeles Times. 11 Oct 1988.
  84. ^ Loth R (12 October 1988). "AIDS Protests close FDA Headquarters". Boston Globe.
  85. ^ Carroll, Rory (2 January 2003). "Swaziland has world's highest Aids rate". The Guardian. London: GMG. ISSN 0261-3077. OCLC 60623878. Retrieved 2 July 2011.
  86. ^ Boseley S (11 July 2003). "Bush vows to join Africa's war on Aids". The Guardian. London: GMG. ISSN 0261-3077. OCLC 60623878. Retrieved 2 July 2011.
  87. ^ "Bogus Aids cures flood Swaziland". mg.co.za. Mail & Guardian. 30 December 2003. Retrieved 2 July 2011.
  88. ^ de Santis D (14 March 2003). . who.int. World Health Organization. Archived from the original on August 27, 2004. Retrieved 2 July 2011.
  89. ^ a b Bradshaw, Steve (9 October 2003). "Vatican: condoms don't stop Aids". the Guardian. Retrieved 21 July 2021. The Aids virus is roughly 450 times smaller than the spermatozoon. The spermatozoon can easily pass through the 'net' that is formed by the condom.
  90. ^ Stanford P (22 April 2008). "Obituary: Cardinal Alfonso López Trujillo". The Guardian. London: GMG. ISSN 0261-3077. OCLC 60623878. Retrieved 2 July 2011.
  91. ^ Devichand, Mukul (27 June 2004). "EU criticises Vatican's condom 'bigotry'". BBC News. Retrieved 21 July 2021.
  92. ^ Parfitt T (October 2003). "Drug addiction and HIV infection on rise in Tajikistan". Lancet. 362 (9391): 1206. doi:10.1016/S0140-6736(03)14560-6. PMID 14570036. S2CID 11892428.
  93. ^ Griffin N, Khoshnood K (July 2010). "Opium trade, insurgency, and HIV/AIDS in Afghanistan: relationships and regional consequences". Asia-Pacific Journal of Public Health. 22 (3 Suppl): 159S–167S. doi:10.1177/1010539510374524. PMID 20566549. S2CID 206615556.
  94. ^ Hankins CA, Friedman SR, Zafar T, Strathdee SA (November 2002). "Transmission and prevention of HIV and sexually transmitted infections in war settings: implications for current and future armed conflicts". AIDS. 16 (17): 2245–52. doi:10.1097/00002030-200211220-00003. PMID 12441795. S2CID 5739709.
  95. ^ Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N, Earhart KC (September 2007). "HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan". Emerging Infectious Diseases. 13 (9): 1327–31. doi:10.3201/eid1309.070036. PMC 2857281. PMID 18252103.
  96. ^ a b c d "UNAIDS and WHO hail new results showing that a once-daily pill for HIV-negative people can prevent them from acquiring HIV". unaids.org. 13 July 2011. Retrieved 4 March 2012.
  97. ^ . aidsmap.com. Archived from the original on 16 May 2012. Retrieved 4 March 2012.
  98. ^ a b . aidsmap.com. 2012. Archived from the original on 24 May 2019. Retrieved 4 March 2012.

May 02, 2024
prevention, aids, prevention, refers, practices, that, prevent, spread, human, immunodeficiency, virus, prevention, practices, undertaken, individuals, protect, their, health, health, those, their, community, instituted, governments, community, based, organiza. HIV prevention refers to practices that aim to prevent the spread of the human immunodeficiency virus HIV HIV prevention practices may be undertaken by individuals to protect their own health and the health of those in their community or may be instituted by governments and community based organizations as public health policies Contents 1 Prevention strategies 1 1 Harm reduction and social strategies 1 2 Advertising and campaigns 1 3 Sexual contact 1 3 1 Condoms and gels 1 3 2 Voluntary male circumcision 1 3 3 Education and health promotion 1 4 Before exposure 1 5 After exposure 1 6 Follow up care 1 7 Mother to child 1 8 Vaccination 1 9 Gene therapy 1 10 Legal system 1 11 Quality in prevention 2 History 2 1 1980s 2 2 From 2003 2 3 From 2011 3 See also 4 ReferencesPrevention strategies editInterventions for the prevention of HIV include the use of nbsp AIDS Prevention Condom dispensers in toilets Barrier methods such as the use of condoms 1 2 or dental dams 3 during sexual activity Antiretroviral medicines or antiretroviral therapy ART Pre exposure prophylaxis Post exposure prophylaxis Voluntary male circumcision see also Circumcision and HIV 4 5 Microbicides for sexually transmitted diseases Low dead space syringes The consistent correct use of condoms is one proven method for preventing the spread of HIV during sexual intercourse 6 In high income countries Prevention of Mother to Child Transmission Programs PMTC including HIV testing of pregnant women antiretroviral treatment 7 counselling about infant feeding and safe obstetric practices avoiding invasive procedures have reduced mother to child transmission to less than 1 Treatment as prevention TasP is also effective in sero different couples where one partner is HIV positive and the other is HIV negative HIV is significantly less likely to be transmitted to the uninfected partner if the HIV positive partner is on treatment 8 It is now known that an if HIV positive person has an undetectable viral load there is no risk of HIV transmission to a sexual partner 9 10 11 Increased risk of contracting HIV correlates with the presence of co infections particularly other sexually transmissible infections Medical professionals recommend treatment or prevention of other infections such as herpes hepatitis A hepatitis B hepatitis C human papillomavirus syphilis gonorrhea and tuberculosis as an indirect way to prevent the spread of HIV infection Doctors treat these conditions with pharmaceutical interventions and or vaccination 12 Nevertheless it is not known if treating other sexually transmitted infections on a population scale is effective in preventing HIV 13 Harm reduction and social strategies edit Harm reduction is defined as policies programmes and practices that aim to minimise negative health social and legal impacts associated with drug use drug policies and drug laws 14 The World Health Organization WHO recognizes that harm reduction is central to the prevention of HIV amongst people who inject drugs PWID and their sexual and drug using partners 15 Social strategies do not require any drug or object to be effective but rather require persons to change their behaviors to gain protection from HIV Some social strategies include citation needed Needle and syringe programmes Supervised injection site Sex education LGBT sex education Safe sex Serosorting Sexual abstinence Each of these strategies has widely differing levels of efficacy social acceptance and acceptance in the medical and scientific communities citation needed Populations who access HIV testing are less likely to engage in behaviors with high risk of contracting HIV 16 so HIV testing is almost always a part of any strategy to encourage people to change their behaviors to become less likely to contract HIV Over 60 countries impose some form of travel restriction either for short or long term stays for people infected with HIV 17 Advertising and campaigns edit Persuasive messages delivered through health advertising and social marketing campaigns which are designed to educate people about the risks of HIV AIDS and simple prevention strategies are also an important way of preventing HIV These persuasive messages have successfully increased people s knowledge about HIV More importantly information sent out through advertising and social marketing also proves to be effective in promoting more favorable attitudes and intentions toward future condom use though they did not bring significant change in actual behaviors except those were targeting at specific behavioral skills 18 19 A 2020 systematic review of 16 studies found that financial education improved self efficacy and lowered vulnerability to HIV in young people in low and middle income countries Many of the studies in the review combined financial education with sexual health education and or counselling 20 Research in health communication also found that importance of advocating critical skills and informing available resources are higher for people with lower social power but not necessarily true for people with more power African American audiences need to be educated about strategies they could take to efficiently manage themselves in health behaviors such as mood control management of drugs and proactive planning for sexual behaviors However these things are not as important for European Americans 19 Sexual contact edit Condoms and gels edit nbsp Condom in the shape of an AIDS ribbon nbsp Various personal lubricants Consistent condom use reduces the risk of heterosexual HIV transmission by about 80 over the long term 21 Where one partner of a couple has HIV infection consistent condom use results in rates of HIV infection for the uninfected person below 1 per year 22 Some data support the equivalence of internal condoms to latex condoms but the evidence is not definitive 23 As of January 2019 condoms are available inside 30 of prisons globally 24 Use of the spermicide nonoxynol 9 may increase the risk of transmission because it causes vaginal and rectal irritation 25 A vaginal gel containing tenofovir a reverse transcriptase inhibitor when used immediately before sex was shown to reduce infection rates by roughly 40 among African women 26 Voluntary male circumcision edit nbsp South Africa 1 millionth voluntary medical male circumcision Studies conducted in sub Saharan Africa have found that circumcision reduces the risk of HIV infection in heterosexual men between 38 and 66 over two years 27 Based on these studies the World Health Organization and UNAIDS both recommended male circumcision as a method of preventing female to male HIV transmission in 2007 28 Whether it protects against male to female transmission is disputed 29 30 and whether it is of benefit in developed countries and among men who have sex with men is undetermined 31 32 33 For men who have sex with men there is some evidence that the penetrative partner has a lower chance of contracting HIV 34 Some experts fear that a lower perception of vulnerability among circumcised men may result in more sexual risk taking behavior thus negating its preventive effects 35 Women who have undergone female genital cutting have an increased risk of HIV 36 The African studies on which this information is based have been criticized for methodological flaws 37 Svoboda and Howe compare them to the lowest common denominator citing selection bias randomization bias experimenter bias inadequate blinding participant expectation bias lack of placebo control inadequate equipoise excessive attrition of subjects failure to investigate non sexual HIV transmission lead time bias and time out discrepancy In addition the 60 figure for risk reduction is dismissed as relative and misleading with an absolute figure of only 1 3 which is considered effectively meaningless given the background noise produced by numerous sources of bias They also point out that the United States has both the highest rates of circumcision and HIV STD infections in the industrialized world casting serious doubt that the former prevents the latter There are also major epidemiological differences between regions in Africa HIV is commonly spread via inadequate infection prevention practices in health clinics while in the US the primary routes of infection are sharing equipment amongst people who use drugs and condomless anal intercourse among MSM Additional criticisms are offered by George Hill 38 Our results clearly show that these African CRFs were methodologically flawed from start to finish From the start there was almost nothing correct with these studies It was quite clear that these studies were unethical They would never have been approved by a single ethics committee in the United States Education and health promotion edit Programs encouraging sexual abstinence do not appear to affect subsequent HIV risk in high income countries 39 Evidence for a benefit from peer education is equally poor 40 Comprehensive sexual education provided at school may decrease high risk behavior 41 A substantial minority of young people continue to engage in high risk practices despite HIV AIDS knowledge underestimating their own risk of becoming infected with HIV 42 Before exposure edit Early treatment of HIV infected people with antiretrovirals protected 96 of partners from infection 43 8 Pre exposure prophylaxis with a daily dose of tenofovir with or without emtricitabine is effective in a number of groups including men who have sex with men couples where one is HIV positive and young heterosexuals in Africa 26 Universal precautions within the health care environment are believed to be effective in decreasing the risk of HIV 44 Intravenous drug use is an important risk factor and harm reduction strategies such as needle exchange programmes and opioid substitution therapy appear effective in decreasing this risk 45 Needle exchange programs also known as syringe exchange programs are effective in preventing HIV among IDUs and in the broader community 46 Pharmacy sales of syringes and physician prescription of syringes have been also found to reduce HIV risk 47 Supervised injection facilities are also understood to address HIV risk in the most at risk populations 48 Multiple legal and attitudinal barriers limit the scale and coverage of these harm reduction programs in the United States and elsewhere around the world 48 The American Centers for Disease Control and Prevention CDC conducted a study in partnership with the Thailand Ministry of Public Health to ascertain the effectiveness of providing people who inject drugs illicitly with daily doses of the antiretroviral drug tenofovir as a prevention measure The results of the study revealed a 48 9 reduced incidence of the virus among the group of subjects who received the drug in comparison to the control group who received a placebo The principal investigator of the study stated in the Lancet medical journal We now know that pre exposure prophylaxis can be a potentially vital option for HIV prevention in people at very high risk for infection whether through sexual transmission or injecting drug use 49 After exposure edit A course of antiretrovirals administered within 48 to 72 hours after exposure to HIV positive blood or genital secretions is referred to as post exposure prophylaxis 50 The use of the single agent zidovudine reduces the risk of subsequent HIV infection fivefold following a needle stick injury 50 Treatment is recommended after sexual assault when the perpetrators are known to be HIV positive but is controversial when their HIV status is unknown 51 Current treatment regimens typically use lopinavir ritonavir and lamivudine zidovudine or emtricitabine tenofovir and may decrease the risk further 50 The duration of treatment is usually four weeks 52 and is associated with significant rates of adverse effects for zidovudine about 70 including nausea 24 fatigue 22 emotional distress 13 and headaches 9 53 Follow up care edit Strategies to reduce recurrence rates of HIV have been successful in preventing reinfection Treatment facilities encourage those previously treated for HIV return to ensure that the infection is being successfully managed New strategies to encouraging retesting have been the use of text messaging and email These methods of recall are now used along with phone calls and letters 54 Mother to child edit Programs to prevent the transmission of HIV from mothers to children can reduce rates of transmission by 92 99 45 55 This primarily involves the use of a combination of antivirals during pregnancy and after birth in the infant but also potentially include bottle feeding rather than breastfeeding 55 56 If replacement feeding is acceptable feasible affordable sustainable and safe mothers should avoid breast feeding their infants however exclusive breast feeding is recommended during the first months of life if this is not the case 57 If exclusive breast feeding is carried out the provision of extended antiretroviral prophylaxis to the infant decreases the risk of transmission 58 Vaccination edit nbsp Various approaches for HIV vaccine development As of 2020 no effective vaccine for HIV or AIDS is known 59 A single trial of the vaccine RV 144 found a partial efficacy rate around 30 and has stimulated optimism in the research community regarding developing a truly effective vaccine 60 Further trials of the vaccine are ongoing 61 62 Gene therapy edit Certain mutations on the CCR5 gene have been known to make certain people unable to catch AIDS Modifying the CCR5 gene using gene therapy can thus make people unable to catch it either 63 64 Legal system edit Laws criminalizing HIV transmission have not been found an effective way to reduce HIV risk behavior and may actually do more harm than good In the past many U S states criminalized the possession of needles without a prescription even going so far as to arrest people as they leave private needle exchange facilities 65 In jurisdictions where syringe prescription status presented a legal barrier to access physician prescription programs had shown promise in addressing risky injection behaviors 66 Epidemiological research demonstrating that syringe access programs are both effective and cost effective helped change state and local laws relating to needle exchange program NEP operations and the status of syringe possession more broadly 67 As of 2006 48 states in the United States authorized needle exchange in some form or allowed the purchase of sterile syringes without a prescription at pharmacies 68 Removal of legal barriers to operation of NEPs and other syringe access initiatives has been identified as an important part of a comprehensive approach to reducing HIV transmission among injection drug users IDUs 67 Legal barriers include both law on the books and law on the streets i e the actual practices of law enforcement officers 69 70 which may or may not reflect the formal law Changes in syringe and drug control policy can be ineffective in reducing such barriers if police continue to treat syringe possession as a crime or participation in NEP as evidence of criminal activity 71 Although most NEPs in the US are now operating legally many report some form of police interference 71 Research elsewhere has shown similar misalignment between law on the books and law on the streets For example in Kyrgyzstan although sex work syringe sales and possession of syringes are not criminalized and possession of small drug amounts has been decriminalized gaps remain between these policies and law enforcement knowledge and practice 72 73 74 To optimize public health efforts targeting vulnerable groups law enforcement personnel and public health policies should be closely aligned Such alignment can be improved through policy training and coordination efforts 74 Quality in prevention edit The EU wide Joint Action on Improving Quality in HIV Prevention is seeking to increase the effectiveness of HIV prevention in Europe by using practical quality assurance QA and quality improvement QI tools 75 History edit1980s edit The Centers for Disease Control was the first organization to recognize the pandemic which came to be called AIDS 76 Their announcement came on June 5 1981 when one of their journals published an article reporting five cases of pneumonia caused by Pneumocystis jirovecii all in gay men living in Los Angeles 77 78 In May 1983 scientists isolated a retrovirus which was later called HIV from an AIDS patient in France 79 At this point the disease called AIDS was proposed to be caused by HIV and people began to consider prevention of HIV infection as a strategy for preventing AIDS citation needed In the 1980s public policy makers and most of the public could not understand that the overlap of sexual and needle sharing networks with the general community had somehow lead to many thousands of people worldwide becoming infected with HIV 76 In many countries leaders and most of the general public denied both that AIDS and the risk behaviors which spread HIV existed outside of concentrated populations 76 In 1987 the United States FDA approved AZT as the first pharmaceutical treatment for AIDS 80 Around the same time ACT UP was formed with one of the group s first goals being to find a way to get access to pharmaceutical drugs to treat HIV 81 When AZT was made publicly available it was extremely expensive and unaffordable to all but the most wealthy AIDS patients 82 The availability of medicine but the lack of access to it sparked large protests around FDA offices 83 84 From 2003 edit In 2003 Swaziland and Botswana reported nearly four out of 10 people were HIV positive 85 Festus Mogae president of Botswana admitted huge infrastructure problems to the international community and requested foreign intervention in the form of consulting in health care setup and antiretroviral drug distribution programs 86 In Swaziland the government chose not to immediately address the problem in the way that international health agencies advised so many people died 87 In world media the governments of African countries began to similarly be described as participating in the effort to prevent HIV actively or less actively There came to be international discussion about why HIV rates in Africa were so high because if the cause were known then prevention strategies could be developed Previously some researchers had suggested that HIV in Africa was widespread because of unsafe medical practices which somehow transferred blood to patients through procedures such as vaccination injection or reuse of equipment In March 2003 the WHO released a statement that almost all infections were in fact the result of unsafe practices in heterosexual intercourse 88 In response to the rising HIV rates Cardinal Alfonso Lopez Trujillo speaking on behalf of the Vatican said that not only was the use of condoms immoral but also that condoms were ineffective in preventing HIV 89 The cardinal was highly criticized by the world health community who were trying to promote condom use as a way to prevent the spread of HIV 90 91 The WHO later conducted a study showing that condoms are 90 effective at preventing HIV 89 In 2001 the United States began a war in Afghanistan related to fighting the Taliban The Taliban however had opposed local opium growers and the heroin trade when the government of Afghanistan fell during the war opium production was unchecked By 2003 the world market had an increase in the available heroin supply in former Soviet states especially an increase in HIV infection was due to injection drug use Efforts were renewed to prevent HIV related to sharing needles 92 93 94 95 From 2011 edit In July 2011 it was announced by the WHO and UNAIDS that a once daily antiretroviral tablet could significantly reduce the risk of HIV transmission in heterosexual couples 96 These findings were based on the results of two trials conducted in Kenya and Uganda and Botswana The Partners PrEP pre exposure prophylaxis trial was funded by the Bill amp Melinda Gates Foundation 97 and conducted by the International Clinical Research Center at the University of Washington The trial followed 4758 heterosexual couples in Kenya and Uganda in which one individual was HIV positive and the other was HIV negative 96 The uninfected HIV negative partner was given either a once daily tenofovir tablet a once daily combination tablet of tenofovir and emtricitabine or a placebo tablet containing no antiretroviral drug These couples also received counselling and had access to free male and female condoms In couples taking tenofovir and tenofovir emtricitabine there was a 62 and 73 decrease respectively in the number of HIV infections as compared to couples who were receiving the placebo 96 A similar result was observed with the TDF2 trial conducted by the United States Centers for Disease Control in partnership with the Botswana Ministry of Health 98 The trial followed 1200 HIV negative men and women in Francistown Botswana a city known to have one of the world s highest HIV infection rates 98 Participants received either a once daily tenofovir emtricitabine combination tablet or a placebo In those taking the antiretroviral treatment there was found to be a 63 decrease in the risk of acquiring HIV as compared to those receiving the placebo 96 The HIV 1 virus has proved to be tenacious inserting its genome permanently into patients DNA forcing patients to take a lifelong drug regimen to control the virus and prevent a fresh attack Now a team of Temple University School of Medicine researchers have designed a way to snip out the integrated HIV 1 genes for good This is one important step on the path toward a permanent cure for AIDS This is the first successful attempt to eliminate latent HIV 1 virus from human cells In a study published by the Proceedings of the National Academy of Sciences PNAS Khalili and colleagues detail how they created molecular tools to delete the HIV 1 proviral DNA full citation needed When deployed a combination of DNA snipping enzyme called a nuclease and targeting strand of RNA called a guide RNA gRNA hunt down the viral genome and excise the HIV 1 DNA From there the cell s own gene repair machinery takes over soldering the loose ends of the genome back together resulting in virus free cells citation needed Since HIV 1 is never cleared by the immune system removal of the virus is required in order to cure the disease The same technique could theoretically be used against a variety of viruses The research shows that these molecular tools also hold promise as a therapeutic vaccine cells armed with the nuclease RNA combination proved impervious to HIV infection See also editAIDS education and training centers HIV denialism List of global issues Relationship between education and HIV AIDS TeachAids World AIDS DayReferences edit How to Use a Female Condom CDC www cdc gov 2019 02 22 Retrieved 2019 10 31 How to Use a Male Condom CDC www cdc gov 2019 02 22 Retrieved 2019 10 31 How to Use a Dental Dam CDC www cdc gov 2019 02 22 Retrieved 2019 10 31 Nandra I 28 March 2008 WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention who int Archived from the original on April 11 2007 Retrieved 3 July 2011 Siegfried N Muller M Deeks JJ Volmink J April 2009 Cochrane HIV AIDS Group ed Male circumcision for prevention of heterosexual acquisition of HIV in men The Cochrane Database of Systematic Reviews 2 CD003362 doi 10 1002 14651858 CD003362 pub2 PMID 19370585 Weller S Davis K et al Cochrane HIV AIDS Group 2002 01 21 Condom effectiveness in reducing heterosexual HIV transmission The Cochrane Database of Systematic Reviews 2012 1 CD003255 doi 10 1002 14651858 CD003255 PMC 8407100 PMID 11869658 White AB Mirjahangir JF Horvath H Anglemyer A Read JS October 2014 Cochrane HIV AIDS Group ed Antiretroviral interventions for preventing breast milk transmission of HIV The Cochrane Database of Systematic Reviews 2014 10 CD011323 doi 10 1002 14651858 CD011323 PMC 10576873 PMID 25280769 a b Anglemyer A Rutherford GW Horvath T Baggaley RC Egger M Siegfried N et al Cochrane HIV AIDS Group April 2013 Antiretroviral therapy for prevention of HIV transmission in HIV discordant couples The Cochrane Database of Systematic Reviews 4 4 CD009153 doi 10 1002 14651858 CD009153 pub3 PMC 4026368 PMID 23633367 Castilla J Del Romero J Hernando V Marincovich B Garcia S Rodriguez C September 2005 Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV Journal of Acquired Immune Deficiency Syndromes 40 1 96 101 doi 10 1097 01 qai 0000157389 78374 45 PMID 16123689 S2CID 42271802 Rodger AJ Cambiano V Bruun T Vernazza P Collins S van Lunzen J et al July 2016 Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV Positive Partner Is Using Suppressive Antiretroviral Therapy JAMA 316 2 171 81 doi 10 1001 jama 2016 5148 PMID 27404185 Rodger AJ Cambiano V Bruun T Vernazza P Collins S Degen O et al June 2019 Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV positive partner taking suppressive antiretroviral therapy PARTNER final results of a multicentre prospective observational study Lancet 393 10189 2428 2438 doi 10 1016 S0140 6736 19 30418 0 PMC 6584382 PMID 31056293 Home Australian STI Management Guidelines www sti guidelines org au Retrieved 2020 07 25 Ng BE Butler LM Horvath T Rutherford GW March 2011 Population based biomedical sexually transmitted infection control interventions for reducing HIV infection The Cochrane Database of Systematic Reviews 3 CD001220 doi 10 1002 14651858 CD001220 pub3 PMID 21412869 What is harm reduction Harm Reduction International Retrieved 2020 02 25 Harm reduction www euro who int 2020 02 25 Retrieved 2020 02 25 Weinhardt LS Carey MP Johnson BT Bickham NL September 1999 Effects of HIV counseling and testing on sexual risk behavior a meta analytic review of published research 1985 1997 American Journal of Public Health 89 9 1397 405 doi 10 2105 ajph 89 9 1397 PMC 1508752 PMID 10474559 HIVTravel Regulations on Entry Stay and Residence for PLHIV Retrieved 2012 02 26 Albarracin D McNatt PS Klein CT Ho RM Mitchell AL Kumkale GT March 2003 Persuasive communications to change actions an analysis of behavioral and cognitive impact in HIV prevention Health Psychology 22 2 166 77 doi 10 1037 0278 6133 22 2 166 PMC 4803280 PMID 12683737 a b Albarracin D Gillette JC Earl AN Glasman LR Durantini MR Ho MH November 2005 A test of major assumptions about behavior change a comprehensive look at the effects of passive and active HIV prevention interventions since the beginning of the epidemic Psychological Bulletin 131 6 856 97 doi 10 1037 0033 2909 131 6 856 PMC 2713787 PMID 16351327 Lee N Beeler Stucklin S Lopez Rodriguez P El Alaoui Faris M Mukaka I 2020 Financial education for HIV vulnerable youth orphans and vulnerable children A systematic review of outcome evidence Campbell Systematic Reviews 16 1 e1071 doi 10 1002 cl2 1071 ISSN 1891 1803 PMC 8356319 Crosby R Bounse S March 2012 Condom effectiveness where are we now Sexual Health 9 1 10 7 doi 10 1071 SH11036 PMID 22348628 Condom Facts and Figures WHO August 2003 Archived from the original on October 18 2012 Retrieved January 17 2006 Gallo MF Kilbourne Brook M Coffey PS March 2012 A review of the effectiveness and acceptability of the female condom for dual protection Sexual Health 9 1 18 26 doi 10 1071 SH11037 PMID 22348629 Moazen B Owusu PN Wiessner P and Stover H 2019 Coverage and Barriers Towards Condom Provision in Prisons A Review of the EvidenceAvailability Coverage and Barriers Towards Condom Provision in Prisons A Review of the EvidenceInstitut fur Suchtforschung ISFF Frankfurt University of Applied Sciences Baptista M Ramalho Santos J November 2009 Spermicides microbicides and antiviral agents recent advances in the development of novel multi functional compounds Mini Reviews in Medicinal Chemistry 9 13 1556 67 doi 10 2174 138955709790361548 PMID 20205637 a b Celum C Baeten JM February 2012 Tenofovir based pre exposure prophylaxis for HIV prevention evolving evidence Current Opinion in Infectious Diseases 25 1 51 7 doi 10 1097 QCO 0b013e32834ef5ef PMC 3266126 PMID 22156901 Siegfried N Muller M Deeks JJ Volmink J April 2009 Male circumcision for prevention of heterosexual acquisition of HIV in men The Cochrane Database of Systematic Reviews 2 CD003362 doi 10 1002 14651858 CD003362 pub2 PMID 19370585 WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention World Health Organization Mar 28 2007 Archived from the original on April 11 2007 Larke N May 2010 Male circumcision HIV and sexually transmitted infections a review British Journal of Nursing 19 10 629 34 doi 10 12968 bjon 2010 19 10 48201 PMC 3836228 PMID 20622758 Eaton L Kalichman SC November 2009 Behavioral aspects of male circumcision for the prevention of HIV infection Current HIV AIDS Reports 6 4 187 93 doi 10 1007 s11904 009 0025 9 PMC 3557929 PMID 19849961 Kim HH Li PS Goldstein M November 2010 Male circumcision Africa and beyond Current Opinion in Urology 20 6 515 9 doi 10 1097 MOU 0b013e32833f1b21 PMID 20844437 S2CID 2158164 Templeton DJ Millett GA Grulich AE February 2010 Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men Current Opinion in Infectious Diseases 23 1 45 52 doi 10 1097 QCO 0b013e328334e54d PMID 19935420 S2CID 43878584 Wiysonge CS Kongnyuy EJ Shey M Muula AS Navti OB Akl EA Lo YR June 2011 Wiysonge CS ed Male circumcision for prevention of homosexual acquisition of HIV in men The Cochrane Database of Systematic Reviews 6 CD007496 doi 10 1002 14651858 CD007496 pub2 PMID 21678366 It s time to talk top The risk of insertive unprotected anal sex Australian Federation of AIDS Organisations Archived from the original on 2014 06 25 Retrieved 2014 06 13 Eaton LA Kalichman S December 2007 Risk compensation in HIV prevention implications for vaccines microbicides and other biomedical HIV prevention technologies Current HIV AIDS Reports 4 4 165 72 doi 10 1007 s11904 007 0024 7 PMC 2937204 PMID 18366947 Utz Billing I Kentenich H December 2008 Female genital mutilation an injury physical and mental harm Journal of Psychosomatic Obstetrics and Gynaecology 29 4 225 9 doi 10 1080 01674820802547087 PMID 19065392 S2CID 36904088 Svoboda Steven Van Howe Robert July 2013 Out of Step Fatal Flaws in the Latest AAP Policy Report on Neonatal Circumcision Journal of Medical Ethics 39 7 BMJ 434 441 doi 10 1136 medethics 2013 101346 JSTOR 43282781 PMID 23508208 S2CID 39693618 Boyle G J Hill G 2011 Sub Saharan African randomised clinical trials into male circumcision and HIV transmission Methodological ethical and legal concerns Journal of Law and Medicine 19 2 316 34 PMID 22320006 Underhill K Operario D Montgomery P October 2007 Abstinence only programs for HIV infection prevention in high income countries The Cochrane Database of Systematic Reviews 4 CD005421 doi 10 1002 14651858 CD005421 pub2 PMID 17943855 Tolli MV October 2012 Effectiveness of peer education interventions for HIV prevention adolescent pregnancy prevention and sexual health promotion for young people a systematic review of European studies Health Education Research 27 5 904 13 doi 10 1093 her cys055 PMID 22641791 Ljubojevic S Lipozencic J 2010 Sexually transmitted infections and adolescence Acta Dermatovenerologica Croatica 18 4 305 10 PMID 21251451 Patel VL Yoskowitz NA Kaufman DR Shortliffe EH September 2008 Discerning patterns of human immunodeficiency virus risk in healthy young adults The American Journal of Medicine 121 9 758 64 doi 10 1016 j amjmed 2008 04 022 PMC 2597652 PMID 18724961 National Institute of Allergy and Infectious Diseases NIAID Treating HIV infected People with Antiretrovirals Protects Partners from Infection NIH News 2011 May Centers for Disease Control CDC August 1987 Recommendations for prevention of HIV transmission in health care settings MMWR Supplements 36 2 1S 18S PMID 3112554 a b Kurth AE Celum C Baeten JM Vermund SH Wasserheit JN March 2011 Combination HIV prevention significance challenges and opportunities Current HIV AIDS Reports 8 1 62 72 doi 10 1007 s11904 010 0063 3 PMC 3036787 PMID 20941553 World Health Organization Effectiveness of Sterile Needle and Syringe Programming in Reducing HIV AIDS Among Injecting Drug Users PDF Evidence for Action Technical Papers Retrieved 7 January 2012 Macalino GE Sachdev DD Rich JD Becker C Tan LJ Beletsky L Burris S June 2009 A national physician survey on prescribing syringes as an HIV prevention measure Substance Abuse Treatment Prevention and Policy 4 13 doi 10 1186 1747 597X 4 13 PMC 2700789 PMID 19505336 a b Beletsky L Davis CS Anderson E Burris S February 2008 The law and politics of safe injection facilities in the United States American Journal of Public Health 98 2 231 7 doi 10 2105 ajph 2006 103747 PMC 2376869 PMID 18172151 SSRN 1088019 Bourke E 14 June 2013 Preventive drug could reduce HIV transmission among injecting drug users The Conversation Australia The Conversation Media Group Retrieved 17 June 2013 a b c HIV exposure through contact with body fluids Prescrire International 21 126 100 1 103 5 April 2012 PMID 22515138 Linden JA September 2011 Clinical practice Care of the adult patient after sexual assault The New England Journal of Medicine 365 9 834 41 doi 10 1056 NEJMcp1102869 PMID 21879901 Young TN Arens FJ Kennedy GE Laurie JW Rutherford GW January 2007 Antiretroviral post exposure prophylaxis PEP for occupational HIV exposure The Cochrane Database of Systematic Reviews 2012 1 CD002835 doi 10 1002 14651858 CD002835 pub3 PMC 8989146 PMID 17253483 Kripke C August 2007 Antiretroviral prophylaxis for occupational exposure to HIV American Family Physician 76 3 375 6 PMID 17708137 Desai M Woodhall SC Nardone A Burns F Mercey D Gilson R August 2015 Active recall to increase HIV and STI testing a systematic review Sexually Transmitted Infections 91 5 314 23 doi 10 1136 sextrans 2014 051930 PMID 25759476 a b Coutsoudis A Kwaan L Thomson M October 2010 Prevention of vertical transmission of HIV 1 in resource limited settings Expert Review of Anti Infective Therapy 8 10 1163 75 doi 10 1586 eri 10 94 PMID 20954881 S2CID 46624541 Siegfried N van der Merwe L Brocklehurst P Sint TT July 2011 Antiretrovirals for reducing the risk of mother to child transmission of HIV infection The Cochrane Database of Systematic Reviews 7 CD003510 doi 10 1002 14651858 CD003510 pub3 PMID 21735394 WHO HIV and Infant Feeding Technical Consultation Held on behalf of the Inter agency Task Team IATT on Prevention of HIV Infections in Pregnant Women Mothers and their Infants Consensus statement PDF October 25 27 2006 Archived PDF from the original on April 9 2008 Retrieved March 12 2008 Horvath T Madi BC Iuppa IM Kennedy GE Rutherford G Read JS January 2009 Interventions for preventing late postnatal mother to child transmission of HIV The Cochrane Database of Systematic Reviews 2009 1 CD006734 doi 10 1002 14651858 CD006734 pub2 PMC 7389566 PMID 19160297 UNAIDS May 18 2012 The quest for an HIV vaccine Reynell L Trkola A 2012 03 02 HIV vaccines an attainable goal Swiss Medical Weekly 142 w13535 doi 10 4414 smw 2012 13535 PMID 22389197 U S Army Office of the Surgeon General March 21 2011 HIV Vaccine Trial in Thai Adults ClinicalTrials gov Retrieved June 28 2011 U S Army Office of the Surgeon General June 2 2010 Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial ClinicalTrials gov Cornu TI Mussolino C Bloom K Cathomen T 2015 Editing CCR5 a novel approach to HIV gene therapy Gene Therapy for HIV and Chronic Infections Advances in Experimental Medicine and Biology Vol 848 pp 117 30 doi 10 1007 978 1 4939 2432 5 6 ISBN 978 1 4939 2431 8 PMID 25757618 Gene Therapy for Controlling HIV Shows Early Promise WebMD Case P Meehan T Jones TS 1998 Arrests and incarceration of injection drug users for syringe possession in Massachusetts implications for HIV prevention Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 18 Suppl 1 S71 5 doi 10 1097 00042560 199802001 00013 PMID 9663627 Macalino GE Sachdev DD Rich JD Becker C Tan LJ Beletsky L Burris S June 2009 A national physician survey on prescribing syringes as an HIV prevention measure Substance Abuse Treatment Prevention and Policy 4 1 13 doi 10 1186 1747 597X 4 13 PMC 2700789 PMID 19505336 a b Burris S Finucane D Gallagher H Grace J August 1996 The legal strategies used in operating syringe exchange programs in the United States American Journal of Public Health 86 8 1161 6 doi 10 2105 ajph 86 8 pt 1 1161 PMC 1380633 PMID 8712281 Chris Barrish 10 June 2006 To stop AIDS breeding ground needle exchange a must many say The News Journal pp A1 A5 Archived from the original on 2 September 2006 Retrieved 10 June 2006 Burris S Blankenship KM Donoghoe M Sherman S Vernick JS Case P et al 2004 Addressing the risk environment for injection drug users the mysterious case of the missing cop The Milbank Quarterly 82 1 125 56 doi 10 1111 j 0887 378x 2004 00304 x PMC 2690204 PMID 15016246 SSRN 937013 Beletsky L Burris S Macalino GE 2005 Attitudes of Police Officers Towards Syringe Access Occupational Needle Sticks and Drug Use A Qualitative Study of One City Police Department in the United States Int l J Drug Pol y 16 4 267 274 doi 10 1016 j drugpo 2005 01 009 S2CID 57946984 SSRN 872756 a b Beletsky L Grau LE White E Bowman S Heimer R February 2011 The roles of law client race and program visibility in shaping police interference with the operation of US syringe exchange programs Addiction 106 2 357 65 doi 10 1111 j 1360 0443 2010 03149 x PMC 3088513 PMID 21054615 CIS News 2009 Kyrgyzstan takes an official course towards humanization of its policy towards drug users a href Template Cite journal html title Template Cite journal cite journal a Cite journal requires journal help Eurasian Harm Reduction Network 2011 Implementation of the political declaration and plan of action on international cooperation towards an integrated and balanced strategy to counter the world drug problem Eurasian Harm Reduction Network a b Beletsky L Thomas R Smelyanskaya M Artamonova I Shumskaya N Dooronbekova A et al December 2012 Policy reform to shift the health and human rights environment for vulnerable groups the case of Kyrgyzstan s Instruction 417 Health and Human Rights 14 2 34 48 PMID 23568946 Quality Action www qualityaction eu a b c Merson MH O Malley J Serwadda D Apisuk C August 2008 The history and challenge of HIV prevention Lancet 372 9637 475 88 doi 10 1016 S0140 6736 08 60884 3 PMID 18687461 S2CID 26554589 Anonymous 1981 Pneumocystis pneumonia Los Angeles Morbidity and Mortality Weekly Report 30 250 52 Sepkowitz KA June 2001 AIDS the first 20 years The New England Journal of Medicine 344 23 1764 72 doi 10 1056 NEJM200106073442306 PMID 11396444 Barre Sinoussi F Chermann JC Rey F Nugeyre MT Chamaret S Gruest J et al May 1983 Isolation of a T lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome AIDS Science 220 4599 868 71 Bibcode 1983Sci 220 868B doi 10 1126 science 6189183 JSTOR 1690359 PMID 6189183 S2CID 390173 Brown J 20 March 1987 AEGiS FDA Approval of AZT aegis com AIDS Education Global Information System Archived from the original on 29 June 2011 Retrieved 2 July 2011 ACT UP 1987 Wall Street Action List of Demands actupny org March 1987 Retrieved 2 July 2011 ACT UP NY Chronology 1989 actupny org 2003 Retrieved 2 July 2011 Police Arrest AIDS Protesters Blocking Access to FDA Offices Los Angeles Times 11 Oct 1988 Loth R 12 October 1988 AIDS Protests close FDA Headquarters Boston Globe Carroll Rory 2 January 2003 Swaziland has world s highest Aids rate The Guardian London GMG ISSN 0261 3077 OCLC 60623878 Retrieved 2 July 2011 Boseley S 11 July 2003 Bush vows to join Africa s war on Aids The Guardian London GMG ISSN 0261 3077 OCLC 60623878 Retrieved 2 July 2011 Bogus Aids cures flood Swaziland mg co za Mail amp Guardian 30 December 2003 Retrieved 2 July 2011 de Santis D 14 March 2003 Expert group stresses that unsafe sex is primary mode of transmission of HIV in Africa who int World Health Organization Archived from the original on August 27 2004 Retrieved 2 July 2011 a b Bradshaw Steve 9 October 2003 Vatican condoms don t stop Aids the Guardian Retrieved 21 July 2021 The Aids virus is roughly 450 times smaller than the spermatozoon The spermatozoon can easily pass through the net that is formed by the condom Stanford P 22 April 2008 Obituary Cardinal Alfonso Lopez Trujillo The Guardian London GMG ISSN 0261 3077 OCLC 60623878 Retrieved 2 July 2011 Devichand Mukul 27 June 2004 EU criticises Vatican s condom bigotry BBC News Retrieved 21 July 2021 Parfitt T October 2003 Drug addiction and HIV infection on rise in Tajikistan Lancet 362 9391 1206 doi 10 1016 S0140 6736 03 14560 6 PMID 14570036 S2CID 11892428 Griffin N Khoshnood K July 2010 Opium trade insurgency and HIV AIDS in Afghanistan relationships and regional consequences Asia Pacific Journal of Public Health 22 3 Suppl 159S 167S doi 10 1177 1010539510374524 PMID 20566549 S2CID 206615556 Hankins CA Friedman SR Zafar T Strathdee SA November 2002 Transmission and prevention of HIV and sexually transmitted infections in war settings implications for current and future armed conflicts AIDS 16 17 2245 52 doi 10 1097 00002030 200211220 00003 PMID 12441795 S2CID 5739709 Todd CS Abed AM Strathdee SA Scott PT Botros BA Safi N Earhart KC September 2007 HIV hepatitis C and hepatitis B infections and associated risk behavior in injection drug users Kabul Afghanistan Emerging Infectious Diseases 13 9 1327 31 doi 10 3201 eid1309 070036 PMC 2857281 PMID 18252103 a b c d UNAIDS and WHO hail new results showing that a once daily pill for HIV negative people can prevent them from acquiring HIV unaids org 13 July 2011 Retrieved 4 March 2012 HIV amp AIDS Information The efficacy of PrEP The Partners PrEP trial aidsmap com Archived from the original on 16 May 2012 Retrieved 4 March 2012 a b HIV amp AIDS Information The efficacy of PrEP The TDF2 trial aidsmap com 2012 Archived from the original on 24 May 2019 Retrieved 4 March 2012 Retrieved from https en wikipedia org w index php title Prevention of HIV AIDS amp oldid 1211250676, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.